RU2387643C2 - Соли n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n`-(2-метилпропилокси)фенилметил)карбамида и их приготовление - Google Patents

Соли n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n`-(2-метилпропилокси)фенилметил)карбамида и их приготовление Download PDF

Info

Publication number
RU2387643C2
RU2387643C2 RU2007115921/04A RU2007115921A RU2387643C2 RU 2387643 C2 RU2387643 C2 RU 2387643C2 RU 2007115921/04 A RU2007115921/04 A RU 2007115921/04A RU 2007115921 A RU2007115921 A RU 2007115921A RU 2387643 C2 RU2387643 C2 RU 2387643C2
Authority
RU
Russia
Prior art keywords
approximately
salt
salt according
powder
values
Prior art date
Application number
RU2007115921/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007115921A (ru
Inventor
Миккель ТЮГЕСЕН (DK)
Миккель ТЮГЕСЕН
Натали ШЛИНГЕР (DK)
Натали ШЛИНГЕР
Бо-Рагнар ТОЛЬФ (SE)
Бо-Рагнар ТОЛЬФ
Фритц БЛАТТЕР (CH)
Фритц Блаттер
Йорг БЕРГХАУЗЕН (DE)
Йорг БЕРГХАУЗЕН
Original Assignee
Акадиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35539440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2387643(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Акадиа Фармасьютикалз Инк. filed Critical Акадиа Фармасьютикалз Инк.
Publication of RU2007115921A publication Critical patent/RU2007115921A/ru
Application granted granted Critical
Publication of RU2387643C2 publication Critical patent/RU2387643C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
RU2007115921/04A 2004-09-27 2005-09-26 Соли n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n`-(2-метилпропилокси)фенилметил)карбамида и их приготовление RU2387643C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61401404P 2004-09-27 2004-09-27
US60/614,014 2004-09-27

Publications (2)

Publication Number Publication Date
RU2007115921A RU2007115921A (ru) 2008-11-10
RU2387643C2 true RU2387643C2 (ru) 2010-04-27

Family

ID=35539440

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007115921/04A RU2387643C2 (ru) 2004-09-27 2005-09-26 Соли n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n`-(2-метилпропилокси)фенилметил)карбамида и их приготовление
RU2007115886/04A RU2417986C2 (ru) 2004-09-27 2005-09-26 Синтез n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n'-(4-(2-метилпропилокси)фенилметил)карбамида, а также его тартрата и кристаллических форм

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2007115886/04A RU2417986C2 (ru) 2004-09-27 2005-09-26 Синтез n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n'-(4-(2-метилпропилокси)фенилметил)карбамида, а также его тартрата и кристаллических форм

Country Status (17)

Country Link
US (6) US7732615B2 (OSRAM)
EP (3) EP2289879B1 (OSRAM)
JP (2) JP4996467B2 (OSRAM)
KR (2) KR101260036B1 (OSRAM)
CN (3) CN101031548B (OSRAM)
AU (2) AU2005289444B2 (OSRAM)
BR (1) BRPI0516063A (OSRAM)
CA (2) CA2580136C (OSRAM)
DK (1) DK1794126T3 (OSRAM)
ES (2) ES2530258T3 (OSRAM)
MX (2) MX2007003433A (OSRAM)
NZ (1) NZ553702A (OSRAM)
PL (2) PL2289879T3 (OSRAM)
RU (2) RU2387643C2 (OSRAM)
SG (2) SG157378A1 (OSRAM)
WO (2) WO2006036874A1 (OSRAM)
ZA (3) ZA200702349B (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263729B1 (en) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) * 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2512639C (en) 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR101260036B1 (ko) * 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
WO2007124136A1 (en) * 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
JP2009537538A (ja) * 2006-05-15 2009-10-29 アカドイア プハルマセウチカルス インコーポレーテッド ピマバンセリン医薬製剤
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2008144665A1 (en) * 2007-05-18 2008-11-27 Acadia Pharmaceuticals Inc. Use of pimavanserin in the treatment of parkinson and symptoms thereof
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MY157197A (en) * 2008-06-30 2016-05-13 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
WO2014085362A1 (en) 2012-11-27 2014-06-05 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR20160040522A (ko) * 2013-06-21 2016-04-14 인트라-셀룰라 써래피스, 인코퍼레이티드. 유리 염기 결정
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN104961671B (zh) * 2014-09-05 2018-01-02 苏州晶云药物科技有限公司 N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
EP3271018B1 (en) 2015-03-02 2020-12-23 Pliva Hrvatska D.O.O. Processes and intermediates for the preparation of pimavanserin
CN104961672B (zh) * 2015-05-20 2017-10-20 沈阳药科大学 一种n‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法
CN104844502B (zh) * 2015-06-05 2018-07-31 齐鲁师范学院 一种匹莫范色林的制备方法
EP3325444B1 (en) * 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
CZ2015601A3 (cs) 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN105111135A (zh) * 2015-09-09 2015-12-02 安徽省逸欣铭医药科技有限公司 取代的尿素衍生物制备方法
CZ2015688A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105153016B (zh) * 2015-10-12 2017-10-03 北京诺康达医药科技有限公司 一种匹莫范色林的制备方法
CN106588753B (zh) * 2015-10-19 2021-07-09 重庆医药工业研究院有限责任公司 一种制备匹马色林的方法
CN106699637A (zh) * 2015-11-17 2017-05-24 重庆医药工业研究院有限责任公司 一种匹马色林单酒石酸盐晶型及其制备方法
CN105924381B (zh) * 2015-12-18 2019-04-16 重庆两江药物研发中心有限公司 一种哌马色林晶型c的制备方法
CN105481757A (zh) * 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
CN105523993A (zh) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
CN107021917B (zh) * 2016-02-02 2020-08-04 江苏恩华药业股份有限公司 哌马色林半酒石酸盐的新晶型及其制备方法
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017172757A1 (en) 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN105820110B (zh) * 2016-05-09 2018-07-24 杭州科巢生物科技有限公司 匹莫范色林合成方法
WO2018049836A1 (zh) * 2016-05-19 2018-03-22 上海诚妙医药科技有限公司 匹莫范色林酒石酸盐的新晶型及其制备方法和用途
CN105859608B (zh) * 2016-05-27 2018-12-28 成都百裕制药股份有限公司 一种制备哌马色林半酒石酸盐晶型b的方法
HU231097B1 (hu) * 2016-07-08 2020-08-28 Egis Gyógyszergyár Zrt. Gyógyászati készítmény előállítására alkalmazható pimavanserin sók
KR102355955B1 (ko) * 2016-09-23 2022-01-25 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US20180208556A1 (en) 2017-01-20 2018-07-26 Sci Pharmtech, Inc. Method for Preparing Pimavanserin
CN106916098A (zh) * 2017-03-07 2017-07-04 江苏艾立康药业股份有限公司 一种哌马色林单酒石酸盐半水合物及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
KR102608479B1 (ko) 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
CN107216271B (zh) * 2017-06-02 2018-11-13 沈阳药科大学 酒石酸匹莫范色林杂质及其制备方法
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
MX2020001757A (es) 2017-08-21 2020-09-07 Acadia Pharm Inc Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
WO2019120250A1 (zh) * 2017-12-22 2019-06-27 广东东阳光药业有限公司 一种哌马色林半酒石酸盐的新晶型及其制备方法
IT201800003736A1 (it) 2018-03-19 2019-09-19 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Pimavanserin
IT201800009690A1 (it) 2018-10-23 2020-04-23 Lundbeck Pharmaceuticals Italy Spa Processo per la produzione di pimavanserina
WO2020092618A1 (en) 2018-10-30 2020-05-07 Acadia Pharmaceuticals Inc. Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin
CN111320568B (zh) * 2018-12-15 2021-12-07 浙江京新药业股份有限公司 一种匹莫范色林的新晶型及其制备方法
ES2906868T3 (es) * 2019-05-22 2022-04-20 Zakl Farmaceutyczne Polpharma S A Intermedio farmacéutico para preparar pimavanserina
WO2021016369A1 (en) 2019-07-22 2021-01-28 Acadia Pharmaceuticals Inc. Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
WO2021030607A1 (en) 2019-08-15 2021-02-18 Acadia Pharmaceuticals Inc. Pimavanserin for treating neurodegenerative diseases
KR20220098179A (ko) 2019-11-08 2022-07-11 케모센트릭스, 인크. 보체 성분 C5a 수용체의 유리 염기 결정질 형태
CN118908883A (zh) 2019-11-08 2024-11-08 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
MX2022005406A (es) * 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
WO2022094230A1 (en) 2020-11-02 2022-05-05 Acadia Pharmaceuticals Inc. Compounds for treating psychosis or depression
CN112920108A (zh) * 2021-01-29 2021-06-08 北京诺康达医药科技股份有限公司 酒石酸匹莫范色林晶型a的制备方法
CN114874103B (zh) * 2022-05-11 2024-09-06 合肥立方制药股份有限公司 一种匹莫范色林中间体4-异丁氧基苄胺的连续合成方法
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2004064738A2 (en) * 2003-01-16 2004-08-05 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
GB1586468A (en) * 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1994027967A1 (en) 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
NZ332173A (en) 1996-04-17 2000-06-23 Du Pont Pharm Co N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
EP0991753A4 (en) 1997-05-08 2001-07-11 Smithkline Beecham Corp PROTEAS INHIBITORS
US6214846B1 (en) * 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US20020163987A1 (en) * 1997-12-12 2002-11-07 British Nuclear Fuels Plc Monitoring a sample containing a neutron source
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
AU762345B2 (en) 1998-10-16 2003-06-26 Asubio Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
AU3771700A (en) 1999-03-24 2000-10-09 Regents Of The University Of California, The Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
BR0010651A (pt) 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
JP4273965B2 (ja) * 2001-06-05 2009-06-03 東洋紡績株式会社 抗血栓性組成物およびそれを有する医療用具
KR100974901B1 (ko) * 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
CN1622940A (zh) 2002-01-17 2005-06-01 通用电气公司 弱配位咪唑烷阴离子的鎓盐作为阳离子引发剂
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) * 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003284899A1 (en) 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
CN100372838C (zh) 2003-02-17 2008-03-05 弗·哈夫曼-拉罗切有限公司 哌啶-苯磺酰胺衍生物
US7628762B2 (en) 2003-03-19 2009-12-08 Suros Surgical Systems, Inc. Adapter assembly for stereotactic biopsy
CA2550735A1 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR101260036B1 (ko) 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2004064738A2 (en) * 2003-01-16 2004-08-05 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease

Also Published As

Publication number Publication date
MX2007003433A (es) 2007-08-06
KR20070083800A (ko) 2007-08-24
AU2005289444A2 (en) 2006-04-06
CA2580129A1 (en) 2006-04-06
ZA200702349B (en) 2008-10-29
RU2417986C2 (ru) 2011-05-10
EP2289879A1 (en) 2011-03-02
WO2006036874A1 (en) 2006-04-06
US20100305329A1 (en) 2010-12-02
JP2008514627A (ja) 2008-05-08
HK1102397A1 (en) 2007-11-16
CA2580136A1 (en) 2006-04-06
CA2580136C (en) 2015-08-18
EP1794125A1 (en) 2007-06-13
US20060205780A1 (en) 2006-09-14
CN101035759B (zh) 2011-06-15
WO2006037043A1 (en) 2006-04-06
AU2005289635A2 (en) 2006-04-06
JP2008514642A (ja) 2008-05-08
CN102153505A (zh) 2011-08-17
RU2007115921A (ru) 2008-11-10
CN101031548B (zh) 2011-04-06
US7923564B2 (en) 2011-04-12
BRPI0516063A (pt) 2008-08-19
US8236960B2 (en) 2012-08-07
EP1794126B1 (en) 2013-03-20
RU2007115886A (ru) 2008-11-10
CN101035759A (zh) 2007-09-12
EP1794126A1 (en) 2007-06-13
AU2005289444B2 (en) 2012-06-14
US20060111399A1 (en) 2006-05-25
SG157378A1 (en) 2009-12-29
SG161221A1 (en) 2010-05-27
ES2412207T3 (es) 2013-07-10
AU2005289444A1 (en) 2006-04-06
US20060106063A1 (en) 2006-05-18
MX2007003403A (es) 2007-05-07
AU2005289635A1 (en) 2006-04-06
US20060205781A1 (en) 2006-09-14
ES2530258T3 (es) 2015-02-27
JP4996467B2 (ja) 2012-08-08
CN102153505B (zh) 2014-10-22
CN101031548A (zh) 2007-09-05
US7868176B2 (en) 2011-01-11
ZA201000714B (en) 2010-10-27
ZA200702345B (en) 2010-04-28
NZ553702A (en) 2010-10-29
US20110184179A1 (en) 2011-07-28
KR20070083799A (ko) 2007-08-24
KR101260036B1 (ko) 2013-05-06
DK1794126T3 (da) 2013-06-24
US7732615B2 (en) 2010-06-08
EP2289879B1 (en) 2014-11-12
PL2289879T3 (pl) 2015-05-29
PL1794126T3 (pl) 2013-08-30
JP5154227B2 (ja) 2013-02-27

Similar Documents

Publication Publication Date Title
JP5154227B2 (ja) Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドの塩及びその調製
US7790899B2 (en) Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
HK1102397B (en) Crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl) carbamide hemi-tartrate

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner